Halozyme Therapeutics Inc
HALO - NASDAQ NMS - GLOBAL MARKET
Industry: Biotechnology
Market Cap: 6.5 B
IPO Date: Jan 30, 2003
Country: US
Currency: USD
Shares Outstanding: 123.2 M
Victory Diversified Stock Fund Q1 2025 Commentary
6/26/2025
In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500®Index benchmark by 95 basis points.
Source: SeekingAlpha
AMG GW&K Small/Mid Cap Core Fund Q1 2025 Commentary
6/26/2025
The AMG GW&K Small/Mid Cap Core Fund returned -8.17% for the first quarter of 2025, compared with -7.50% for its benchmark, the Russell 2500 Index.
Source: SeekingAlpha
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6/20/2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobuli
Source: Yahoo
Halozyme Therapeutics, Inc. Announces Argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
6/20/2025
Halozyme Therapeutics, Inc. announced that argenx received European Commission approval of VYVGART® 1000mg developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme ,...
Source: Finnhub
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
6/17/2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Source: Yahoo
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
6/16/2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Source: Yahoo
Halozyme Therapeutics: The Waters Become Muddled
6/15/2025
Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.
Source: SeekingAlpha
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
6/13/2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Source: Yahoo
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
6/12/2025
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Source: Yahoo
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10
6/9/2025
Presenter SpeechCorinne Jenkins Good morning, everyone, and thanks for joining us here at the Goldman Sachs health care conference. We're thrilled to be joined today with a team from Halozyme. And...
Source: Finnhub
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
6/5/2025
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Source: Yahoo
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
6/4/2025
Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck’s (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Published first on TheFly – the ultimate source for real-time, market-moving br
Source: Yahoo
Merck granted review of Halozyme patent claims by PTAB
6/4/2025
The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 of U.S. Patent No. 11,952,600, according to a post to the site of the USPTO. In consideration of “the Petition, Preliminary Response, Reply, Sur-Reply, and the evidence of record, we determine that the information presented shows that it is more likely than not that Petitioner would prevail in estab
Source: Yahoo
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme
6/4/2025
Sterling, BJ's, Molina, and Halozyme stand tall with robust earnings growth and high interest coverage in June picks.
Source: Yahoo
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
5/29/2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Source: Yahoo
Halozyme to Participate at Upcoming Investor Conferences
5/28/2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences.
Source: Yahoo
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
5/28/2025
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Source: Yahoo